12/3/2013 8:57:53 AM
RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) (“Salix”) today announced the commencement of a cash tender offer by its indirect wholly owned subsidiary, Willow Acquisition Sub Corporation (“Purchaser”), to purchase all of the issued and outstanding shares of common stock, par value $0.0001 per share, of Santarus, Inc. (NASDAQ:SNTS) (“Santarus”) at a purchase price of $32.00 per share, net to the seller in cash, without interest and subject to any required withholding taxes. The tender offer is being made pursuant to an Offer to Purchase, dated December 3, 2013, and in connection with the previously announced definitive merger agreement, dated November 7, 2013, among Salix, Salix Pharmaceuticals, Inc., a wholly owned subsidiary of Salix (“Intermediary”), Purchaser and Santarus.
Help employers find you! Check out all the jobs and post your resume.
comments powered by